Dr Eriksen was an employee and owns stock in Eli Lilly. Drs Donley and Dalsky are employees of Eli Lilly and Company. Dr San Martin was an employee at Eli Lilly and Company during the course of this study. Dr Meunier serves as a consultant for Aventis, Eli Lilly and Company, MSD, Nycomed, Procter & Gamble, and Servier. Dr Arlot received a grant from Eli Lilly and Company. Dr Boivin serves as a consultant for Eli Lilly and Company and Servier. All other authors have no conflict of interest.
Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters†
Article first published online: 14 MAR 2005
Copyright © 2005 ASBMR
Journal of Bone and Mineral Research
Volume 20, Issue 7, pages 1244–1253, July 2005
How to Cite
Arlot, M., Meunier, P. J., Boivin, G., Haddock, L., Tamayo, J., Correa-Rotter, R., Jasqui, S., Donley, D. W., Dalsky, G. P., Martin, J. S. and Eriksen, E. F. (2005), Differential Effects of Teriparatide and Alendronate on Bone Remodeling in Postmenopausal Women Assessed by Histomorphometric Parameters. J Bone Miner Res, 20: 1244–1253. doi: 10.1359/JBMR.050309
- Issue published online: 4 DEC 2009
- Article first published online: 14 MAR 2005
- Manuscript Accepted: 10 MAR 2005
- Manuscript Revised: 21 JAN 2005
- Manuscript Received: 16 JUL 2004
- bone remodeling;
- bone formation;
An 18-month randomized double-blind study was conducted in postmenopausal women with osteoporosis to compare the effects of once-daily teriparatide 20 μg with alendronate 10 mg on bone histomorphometry. Biopsies were obtained from 42 patients. Indices of bone formation were significantly higher after 6 or 18 months of teriparatide compared with alendronate treatment.
Introduction: Alendronate and teriparatide increased BMD, assessed by DXA, by different mechanisms of action, supported by changes in biochemical markers of bone turnover. The purpose of this cross-sectional study was to explore the differential effects of these two osteoporosis treatments at the bone tissue level by examining bone histomorphometric parameters of bone turnover after either 6 or 18 months of treatment.
Materials and Methods: Patients were a cohort from a randomized parallel double-blind study conducted to compare the effects of once-daily teriparatide 20 μg and alendronate 10 mg in postmenopausal women with osteoporosis. Transiliac crest bone biopsies were obtained after tetracycline double labeling from 42 patients treated for 6 months (n = 23) or 18 months (n = 14); 5 additional patients were biopsied from contralateral sides at 6 and 18 months. Biopsy specimens adequate for quantitative analysis were analyzed by 2D histomorphometry from 17 patients at 6 months (teriparatide, n = 8; alendronate, n = 9) and 15 patients at 18 months (teriparatide, n = 8; alendronate, n = 7). Data were analyzed by two-sample tests.
Results: Histomorphometric indices of bone formation were significantly and markedly greater in the teriparatide group than in the alendronate group at 6 and 18 months, whereas indices of bone resorption were only significantly greater in the teriparatide group than in the alendronate group at 6 months. Bone formation and activation frequency were significantly lower at 18 months compared with 6 months in the teriparatide group, returning to levels comparable with untreated postmenopausal women. In the teriparatide group, the peak in histomorphometric bone formation indices coincided with peak levels for N-terminal propeptide of type I collagen, a biochemical marker of bone formation. The degree of mineralization was lower at 18 months than at 6 months with treatment in both groups but was not different between groups.
Conclusions: These results confirm the opposite mechanisms of action of teriparatide and alendronate on bone remodeling and confirm the bone formation effect of teriparatide.